This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

SAC Upped Dendreon Exposure Before Blowup

Stocks in this article: DNDN AMGN BIIB GILD AMRN ACOR PFE

BOSTON ( TheStreet) -- More evidence emerged Monday suggesting billionaire hedge fund manager Steven Cohen lost a bundle when Dendreon (DNDN) blew up.

Cohen's SAC Capital Advisors increased its monstrous Dendreon position by 5% to 8.6 million shares, or $351 million, at the end of the June quarter, according to the fund's 13F filed with the Securities and Exchange Commission Monday night.

Dendreon was the largest single stock holding by position value in SAC's portfolio, according to the new 13F.

It's not known if Cohen sold any or all of his Dendreon position (or was hedged with a short position) before the company reported disastrous second-quarter results on Aug. 3 due to slower-than-expected sales of its Provenge prostate cancer therapy. But if Cohen held those 8.6 million shares of Dendreon, his fund would have lost more than $200 million.

Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F filed SEC within 45 days of the end of a quarter. Funds aren't required to report short positions betting on declines. SAC Capital Advisors ended the second quarter with 2,033 reported holdings with a market value of $17.4 billion.

In other biotech and drug holdings, SAC eliminated entirely or sold large stakes in Amgen (AMGN), Biogen Idec (BIIB), Allos Therapeutics (ALTH), Cubist Pharmaceuticals (CBST), Gilead Sciences (GILD) and Inspire Pharmaceuticals (ISPH) during the second quarter, according to the fund's 13F.

SAC increased positions in Acorda Therapeutics (ACOR), Human Genome Sciences (HGSI), Amarin (AMRN), InterMune (ITMN), Pfizer (PFE), and Amylin Pharmaceuticals (AMLN).

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs